OBLN vs. CATX, INFU, NSPR, CTCX, TMDIF, HSAQ, RVP, PETV, GBS, and BTCY
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Perspective Therapeutics (CATX), InfuSystem (INFU), InspireMD (NSPR), Carmell (CTCX), Titan Medical (TMDIF), Health Sciences Acquisitions Co. 2 (HSAQ), Retractable Technologies (RVP), PetVivo (PETV), GBS (GBS), and Biotricity (BTCY). These companies are all part of the "medical" sector.
Obalon Therapeutics vs. Its Competitors
Perspective Therapeutics (NYSE:CATX) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.
54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Perspective Therapeutics had 13 more articles in the media than Obalon Therapeutics. MarketBeat recorded 13 mentions for Perspective Therapeutics and 0 mentions for Obalon Therapeutics. Perspective Therapeutics' average media sentiment score of 0.54 beat Obalon Therapeutics' score of 0.00 indicating that Perspective Therapeutics is being referred to more favorably in the media.
Perspective Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500.
Obalon Therapeutics has higher revenue and earnings than Perspective Therapeutics.
Perspective Therapeutics currently has a consensus price target of $12.56, suggesting a potential upside of 248.77%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Perspective Therapeutics is more favorable than Obalon Therapeutics.
Obalon Therapeutics has a net margin of -776.76% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Obalon Therapeutics' return on equity.
Summary
Perspective Therapeutics beats Obalon Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OBLN) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access